GMDA - Gamida clibs 5.6% despite a Q4 miss provides 2021 guidance

Gamida ([[GMDA]] +4.7%) Q4 net loss for 2020 was $72.7M, compared to a net loss of $34.4M in 2019.GAAP EPS of -$1.66 misses consensus by $0.35.R&D expenses in 2020 were $41.4M, compared to $31.5M in 2019.As of December 31, 2020, had total cash and cash equivalents of $127.2 million, compared to $55.4 million as of December 31, 2019.In addition, on February 16, 2020, company announced the sale of $75M exchangeable senior notes due in 2026 to Highbridge Capital Management.Guidance 2020: Company expects cash used for ongoing operating activities in 2021 to range from $100M-120M; expects that its current cash and cash equivalents will support the company’s ongoing operating activities into 2H of 2022.Expected 2021 milestones: Omidubicel: BLA submission to the FDA in Q4 2021 and commercial readiness activities underway for potential launch at approval. GDA-201: submit company-sponsored IND application to the FDA and initiate a Phase 1/2 clinical study in NHL in the second half of

For further details see:

Gamida clibs 5.6% despite a Q4 miss, provides 2021 guidance